U
ATRS

UBS’s Antares Pharma, Inc. ATRS Stock Holding History

UBS’s Portfolio ATRS Stock Details ATRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		– Sell
-6,900
Closed -$24K – 10960
2014
Q1 		$24K Sell
6,900
-800
-10% -$3.55K ﹤0.01% 7863
2013
Q4 		$34K Buy
7,700
+6,700
+670% +$27.3K ﹤0.01% 7481
2013
Q3 		$4K Sell
1,000
-13,700
-93% -$59.8K ﹤0.01% 9614
2013
Q2 		$61K Buy
+14,700
New +$56.8K ﹤0.01% 6500

Other funds holding ATRS

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
WHI
William Harris Investors Chicago, Illinois $347M AUM 3.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

UBS's ATRS Position: Q3 2014 in Review

UBS opened a new position in Antares Pharma, Inc. (ATRS) in Q3 2014: 1,000 shares worth $2K. The stake represents ﹤0.01% of the portfolio and ranks #10043 among its holdings. This is a return to the name: UBS previously reported a position in ATRS as recently as Q4 2013.

UBS first reported a position in ATRS in Q2 2013 and has held it in 3 quarters since. The position peaked at $232K in Q2 2013. 82 funds tracked by Wall St. Rank hold ATRS as of Q3 2014.

  • UBS held 1,000 shares of Antares Pharma, Inc. worth $2K as of Q3 2014.
  • Antares Pharma, Inc. was a new UBS position in Q3 2014.
  • Antares Pharma, Inc. made up ﹤0.01% of UBS's portfolio in Q3 2014, its #10043 holding.
  • UBS first reported a position in Antares Pharma, Inc. in Q2 2013 and has held it in 3 quarters since.
  • UBS's Antares Pharma, Inc. position peaked at $232K in Q2 2013.
  • 82 funds tracked by Wall St. Rank held Antares Pharma, Inc. as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.